Expert Stock Recommendations from Anand Rathi's Technical Research Head
In a detailed market analysis, Mehul Kothari, Deputy Vice President of Technical Research at Anand Rathi Shares and Stock Brokers, has identified three promising stocks for investors. The recommendations focus on Syrma SGS Technology, Sagility India, and Emcure Pharmaceuticals, each presenting unique technical setups that suggest potential upside opportunities in the current trading environment.
Syrma SGS Technology: Reversal Setup Near Critical Support
Buy Range: ₹745 | Stop Loss: ₹660 | Target: ₹880
Syrma SGS Technology is currently positioned near a crucial support zone between ₹730 and ₹745. This level has historically served as a robust demand area, providing a foundation for price stability. The stock maintains a constructive broader trend structure by holding above its long-term moving averages, indicating underlying strength in the primary uptrend.
Momentum indicators further support a potential rebound. The Relative Strength Index (RSI) is approaching oversold territory, signaling that recent selling pressure may be diminishing. This confluence of technical support and weakening downside momentum points to a possible recovery move if buying interest emerges at current levels, making it an attractive entry point for traders.
Sagility India: Oversold Bounce from Key Demand Zone
Buy Range: ₹39–₹37 | Stop Loss: ₹32 | Target: ₹46–₹50
Sagility India has experienced a sharp corrective phase and is now nearing a significant demand zone around ₹37–₹39. This area represents a key support level where the stock has historically shown signs of price stabilization. Technically, the RSI has entered the oversold region, suggesting that the ongoing selling pressure could be nearing exhaustion.
Additionally, the stock is trading close to important moving average supports, which may act as a cushion and attract fresh buying interest. The combination of oversold momentum conditions and proximity to these support levels indicates a high probability of a technical rebound, offering a strategic entry for investors looking to capitalize on potential recovery.
Emcure Pharmaceuticals: Trend Continuation with Momentum Support
Buy Range: ₹1,340–₹1,320 | Stop Loss: ₹1,220 | Target: ₹1,535
Emcure Pharmaceuticals has demonstrated signs of stabilization following a recent correction and is currently trading near a strong support zone around ₹1,300. Technically, the stock exhibits improving momentum characteristics, with indicators suggesting that downside pressure is easing. The broader trend structure remains positive as the price continues to trade above long-term moving averages, reflecting sustained strength in the underlying trend.
Improving volume participation indicates renewed interest from market participants, adding to the bullish outlook. This blend of technical factors suggests the potential for a continuation of the upward move if the support zone holds, making it a compelling pick for those seeking trend-following opportunities.
Disclaimer: The recommendations and views on the stock market provided by experts are their own and do not represent the views of The Times of India or its affiliates. Investors are advised to conduct their own research or consult with financial advisors before making any investment decisions.
